Fennec Pharmaceuticals (STU:RV41) Other Net Income (Loss) : €-0.35 Mil (TTM As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals Other Net Income (Loss)?

Fennec Pharmaceuticals's Other Net Income (Loss) for the three months ended in Dec. 2024 was €-0.35 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.35 Mil.

Fennec Pharmaceuticals's quarterly Other Net Income (Loss) stayed the same from Jun. 2024 (€0.00 Mil) to Sep. 2024 (€0.00 Mil) but then declined from Sep. 2024 (€0.00 Mil) to Dec. 2024 (€-0.35 Mil).

Fennec Pharmaceuticals's annual Other Net Income (Loss) stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil).

Fennec Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Fennec Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Other Net Income (Loss) Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Fennec Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-0.35

Fennec Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.35 Mil.

Fennec Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

FENC:USA FRX:Canada

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals Headlines

No Headlines